Good evening :)
$
₹
INmune Bio Inc

INmune Bio Inc

INMB

NASDAQ
Asset Logo

INmune Bio Inc

INMB

NASDAQ
$1.450.68% (-0.01)
$
₹
$1.450.68% (-0.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $40.5M the stock is ranked 5124

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.80
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.67
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 2 analysts reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+379.45%

Earnings Growth

+43.7%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 379.45% growth, versus a trailing 3-year CAGR of -40.78%.

2026
Current$1.46Baseline
Analyst Target - 1 year
Target$7+379.45%

All values in $

202220232024202520262027$4.08$6.85$9.62Target+379.45%
2026
Current$1.46Baseline
Analyst Target - 1 year
Target$7+379.45%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.19Baseline
Forecast for Dec 2026
High$-0.67+43.7%
Average$-0.67+43.7%
Low$-0.67+43.7%

All values in $

202120222023202420252026-1.86-1.52-1.67-2.11-1.19Low+43.7%Average+43.7%High+43.7%
2025
Current$-1.19Baseline
Forecast for Dec 2026
High$-0.67+43.7%
Average$-0.67+43.7%
Low$-0.67+43.7%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-6.4
-5.2
-5.4
-1.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.010000.0500000
Net Income-11.02-9.74-12.09-9.21-9.73-24.45-6.47-5.26-5.40-1.27
Net Profit Margin-78750%----19478%-----
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
INmune Bio Inc -2.80-
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare INMB with any stock or ETF
Compare INMB with any stock or ETF
Comparing from
INMB
ABBV
AMGN
Loading...

Frequently asked questions

  1. INmune Bio Inc (INMB) share price today is $1.45 as of October 26, 2026 at 11:13 PM IST. The stock touched a day high of $1.49 and a day low of $1.41.

  2. INmune Bio Inc stock trades on NASDAQ under the ticker symbol INMB.

  3. INmune Bio Inc's market capitalization is $40.52M as of October 26, 2026 at 11:13 PM IST.

  4. INmune Bio Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. INmune Bio Inc's price-to-book (P/B) ratio is 2.80 as of October 26, 2026.

  6. Yes, You can buy INmune Bio Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy INmune Bio Inc shares in three steps: 1. Search INmune Bio Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since INmune Bio Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in INmune Bio Inc (INMB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 6.8965 shares at the current price of $1.45.

Loading...